8-K
Chemomab Therapeutics Ltd. (CMMB)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest eventreported): April 15, 2020
ANCHIANO THERAPEUTICS LTD.
(Exact name of registrant as specifiedin its charter)
| State of Israel | 001-38807 | N/A |
|---|---|---|
| (State or other jurisdiction<br><br> <br>of incorporation) | (Commission<br><br> <br>File Number) | (IRS Employer<br><br> <br>Identification No.) |
| One Kendall Square, Building 600, Suite 6-106<br><br> <br>Cambridge, MA | 02139 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number,including area code: +1 (857) 259-4622
5 Kiryat Hamada St., PO Box 45032
Jerusalem, Israel, 9777401
(Former name or former address, if changedsince last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written<br>communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
|---|---|---|
| ¨ | Soliciting<br>material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| --- | --- | |
| ¨ | Pre-commencement<br>communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| --- | --- | |
| ¨ | Securities registered pursuant to Section 12(b) of<br>the Act: | |
| --- | --- | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| --- | --- | --- |
| American Depositary Shares, each representing five ordinary shares, no par value per share | ANCN | Nasdaq Capital Market |
| Ordinary shares, no par value per share | N/A | Nasdaq Capital Market* |
* Not for trading; only in connection with the registration of American Depositary Shares.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
| Item 3.01. | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
|---|
On April 15, 2020, Anchiano Therapeutics Ltd. (the “Company”) received a deficiency letter (the “Nasdaq Letter”) from the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price of the Company’s American Depositary Shares (“ADS”) has not been maintained at the minimum required closing bid price of at least $1.00 per ADS, as required for continued listing on the Nasdaq Capital Market.
The Nasdaq Letter does not result in the immediate delisting of the Company’s ADSs, and the Company’s ADSs will continue to trade uninterrupted on the Nasdaq Capital Market under the symbol “ANCN.”
In accordance with the Nasdaq Listing Rules, the Company has been given 180 calendar days, or until October 12, 2020, to regain compliance with the minimum bid price requirement. If at any time before October 12, 2020, the closing bid price of the Company's ADSs is at least $1.00 per ADS for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it complies with the minimum bid price requirement.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANCHIANO THERAPEUTICS LTD. | ||
|---|---|---|
| Date: April 15, 2020 | By: | **/s/**Dr. Frank G. Haluska |
| Name: Dr. Frank G. Haluska | ||
| Title: Chief Executive Officer |